Identification of Novel TRPC5 Inhibitors by Pharmacophore-Based and Structure-Based Approaches

Shuxiang Li,Shuqun Zhang,Dingyuan Chen,Xuan Jiang,Bin Liu,Hongbin Zhang,Munikishore Rachakunta,Zhili Zuo

DOI: https://doi.org/10.1016/j.compbiolchem.2020.107302

IF: 3.737

2020-08-01

Computational Biology and Chemistry

Abstract:<p>Canonical transient receptor potential-5 (TRPC5), which belongs to the subfamily of transient receptor potential (TRP) channels is a non-selective cation channel mainly expressed in the central nervous system and shows more restricted expression in the periphery. TRPC5 plays a crucial role in human physiology and pathology, for instance, anxiety, depression, epilepsy, pain, memory and chronic kidney disease (CKD). However, due to lack of the effective and selective inhibitors, its physiological and pathological mechanism remains so far unknown. It is therefore pivotal to identify potential TRPC5 inhibitors; we have approached ligand-based virtual screening (LBVS) and structure-based virtual screening (SBVS) methods. The pharmacophore models of TRPC5 antagonists generated by using the HypoGen and HipHop algorithms were used as a query model for the screening of potential inhibitors against the Specs database. The resultant hits from LBVS were further screened by SBVS. SBVS was based on the homology model generation of human TRPC5, binding site identification, molecular dynamics optimization to carry out molecular docking studies. In our systematic screening approaches, we have identified 7 hits compounds with comparable dock score after Lipinski and Veber rules, ADMET, PAINS analysis, cluster analysis, and similarity analysis. In conclusion, this current research provides novel backbones for the new-generation of TRPC5 inhibitors.</p>

biology,computer science, interdisciplinary applications

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify new types of TRPC5 inhibitors. Specifically, the TRPC5 (Transient Receptor Potential Canonical 5) channel plays an important role in human physiological and pathological processes, such as anxiety, depression, epilepsy, pain, memory, and chronic kidney disease (CKD). However, due to the lack of effective selective inhibitors, the specific mechanism of action of TRPC5 remains unclear. Therefore, the development of highly efficient, reliable, and selective TRPC5 inhibitors is crucial for studying its exact role in human diseases and developing new therapeutic drugs. To achieve this goal, researchers adopted pharmacophore - based and structure - based virtual screening methods (LBVS and SBVS) to discover potential TRPC5 inhibitors. The following are the specific research steps: 1. **Pharmacophore - based virtual screening (LBVS)**: - Use the HipHop and HypoGen algorithms to generate pharmacophore models, and use these models as query models to screen the Specs database. - Evaluate the effectiveness and discrimination ability of the generated pharmacophore models through the validation test set. 2. **Structure - based virtual screening (SBVS)**: - Construct a human homologous model of TRPC5 and optimize it through molecular dynamics. - Conduct binding site identification and molecular docking studies to further screen potential inhibitors. 3. **Compound screening and analysis**: - Screen compounds through Lipinski's rules, Veber's rules, ADME properties, and PAINS filters. - Perform cluster analysis and similarity analysis on the screened compounds, and finally determine 7 potential TRPC5 inhibitors. Through these methods, researchers hope to find TRPC5 inhibitors with novel structures and potential activities, providing a basis for the design of a new generation of TRPC5 inhibitors.

Identification of Novel TRPC5 Inhibitors by Pharmacophore-Based and Structure-Based Approaches

Discovery of novel modulators targeting human TRPC5: Docking-based virtual screening, molecular dynamics simulation and binding affinity predication

Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

Identification of novel selective TRPV3 antagonists based on virtual screening, molecular docking and bioassay

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

Structural Basis for Human TRPC5 Channel Inhibition by Two Distinct Inhibitors.

Three-Dimensional Quantitative Structure-Activity Relationship Study of Transient Receptor Potential Vanilloid 1 Channel Antagonists Reveals Potential for Drug Design Purposes

Insights into the discovery of new 5-HT1A receptor ligands:receptor based pharmacophore

A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

A Precise Microfluidic Assay in Single‐Cell Profile for Screening of Transient Receptor Potential Channel Modulators

Identification of Novel P2X7R Antagonists by Using Structure‐based Virtual Screening and Cell‐based Assays

Synthesis, high-throughput screening and pharmacological characterization of β–lactam derivatives as TRPM8 antagonists

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

Discovery of a Novel 5-HT2A inhibitor by pharmacophore-based virtual screening

Ligand-based pharmacophore modeling, virtual screening and biological evaluation to identify novel TGR5 agonists